Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeMeMe: Metformin and Lifestyle for Age-related Disease Prevention
NCT02960711Phase 3Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2014
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liquid metformin (Aspargo Labs) in chronic condition (4 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Total incidence of age related chronic diseases at 5 years. Started Feb 2014; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
chronic condition
Beyond the preview
Go deeper on NCT02960711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960711.